This study is for adult women who have advanced or recurrent endometrial (uterine) cancer. The purpose is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating uterine cancer.
This study is for women with endometrial cancer. This study is being done to see if by adding a drug or drugs that target HER2 proteins in addition to the usual combination of chemotherapy drugs.
This study is for women with advanced uterine leiomyosarcoma. The study is being done to see if the combination of olaparib and temozolomide is better for treatment after initial chemotherapy has stopped working.
This study is for female subjects that have a very specific type of recurrent ovarian, peritoneal, or fallopian tube cancer. These patients must have completed 1 round of chemotherapy for their cancer type. The study is testing an "investigational" (not yet FDA approved) drug called MIRV (Mirvetuximab Soravtansine). The primary purpose of this study is to determine the effectiveness and safety of the study drug to determine what effects, if any, it has on subjects. Subjects may remain in the study for up to 2 years.
They study is for patients that have have been diagnosed with platinum-resistant or platinum-refractory ovarian cancer (PRROC) which includes fallopian tube cancer and peritoneal carcinomatosis (a form of cancer that affects the thin membrane that surrounds your abdominal organs). The investigational drug used in this study is Olvi-Vec. The main purpose of the study is to determine how women diagnosed with PRROC will best respond to receiving Olvi-Vec followed by platinum-doublet chemotherapy (platinum-based chemotherapy such as carboplatin or cisplatin are given with a non-platinum based chemotherapy, including gemcitabine, paclitaxel, docetaxel, nab-paclitaxel, or pegylated liposomal doxorubicin [PLD]) along with bevacizumab, known as the Experimental Arm. Participants can expect to be in this study for up to 36 months.